Aerosolized ribavirin: the most expensive drug for pneumonia

Transplant Infectious Disease

Volumn 18, Issue 4, 2016, Pages 634-636

  Chemaly, R F ^a   Aitken, S L ^a   Wolfe, C R ^b   Jain, R ^c   Boeckh, M J ^d,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

average wholesale price; cost; hematologic malignancy; hematopoietic stem cell transplantation; pediatrics; respiratory syncytial virus

Indexed keywords

BLINATUMOMAB; RIBAVIRIN;

AEROSOL; ARTICLE; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT REGULATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MEDICAID; MEDICARE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84981244678     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12551     Document Type: Article

References (14)

1. Pollack A. Drug Goes from $13.50 a Tablet to $750, Overnight. New York: The New York Times, 2015.
2. Rockoff JD, Silverman E. Pharmaceutical Companies Buy Rivals’ Drugs, Then Jack Up the Prices. New York, NY: The Wall Street Journal, Dow Jones & Company, 2015.
3. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014; 123 (21): 3263–3268.
4. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 59 (Suppl 5): S344–S351.
5. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 2013; 57 (12): 1731–1741.
6. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016; 18 (2): 210–215.
7. Red Book Online (Database Online). Greenwood Village, CO: Truven Health Analytics, 2016.
8. Pear R. Medicare, Reversing Itself, Will Pay More for an Expensive New Cancer Drug. New York: The New York Times, 2015.
9. Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant 2013; 48 (2): 294–300.
10. Marcelin JR, Wilson JW, Razonable RR, Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16 (2): 242–250.
11. Casey J, Morris K, Narayana M, Nakagaki M, Kennedy GA. Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2013; 48 (12): 1558–1561.
12. Park SY, Baek S, Lee SO, et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother 2013; 57 (2): 983–989.
13. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood 2016; 127 (22): 2682–2692.
14. Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Practice 2014; 10 (4): e208–e211.